Compare United States Brent Oil Fund LP (BNO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Viatris Inc — how do they compare? United States Brent Oil Fund LP trades at $46.49, while Viatris Inc trades at $16.49 (market cap $18.99B). The key difference: Viatris Inc pays a 2.94% dividend while United States Brent Oil Fund LP pays none, and Viatris Inc is trading nearer its 52-week high, United States Brent Oil Fund LP nearer its low. Which is the better fit depends on your goals.
| BNO | VTRS | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $17.39 |
52-Week Low | $27.20 | $8.74 |
Market Cap | — | $18.99B |
Enterprise Value | — | $31.20B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO, a US-listed oil-focused stock, trades at $46.00, up 9.13% on the day, driven by escalating Middle East tensions that have pushed crude prices to one-month highs. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI at 86 suggests overbought conditions. Recent news highlights supply risks from U.S.-Iran hostilities, including blockades and strikes, which are boosting energy sector sentiment and driving volatility.
The outlook for BNO remains heavily tied to geopolitical developments and oil price momentum. Upside potential exists if supply disruptions persist, but risks include rapid de-escalation or demand weakness. Investors should weigh the stock's sensitivity to crude fluctuations against current bullish technical and sentiment signals.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
